22:48 , Mar 30, 2017 |  BioCentury  |  Emerging Company Profile

Resisting resistance

While many companies are attempting to counteract mutations in cancer that result in resistance, ApoGen Biotechnologies Inc. is instead targeting a mechanism that causes resistance mutations to develop. The approach could prolong responses to cancer...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
00:57 , Dec 13, 2016 |  BC Extra  |  Financial News

ApoGen debuts with $7M

Accelerator Corp. (Seattle, Wash.) said it participated in a $7 million series A financing for oncology newco ApoGen Biotechnologies Inc. (Seattle, Wash.). Also investing were the AbbVie Ventures arm of AbbVie Inc. (NYSE:ABBV), Alexandria Venture...
07:00 , Nov 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting APOBEC3B could help treat estrogen receptor-positive, tamoxifen-resistant breast cancer. In estrogen receptor-positive breast cancer patients treated with tamoxifen, high primary tumor expression of APOBEC3B correlated with...